Workflow
智能审核2.0
icon
Search documents
国新健康:AI与数据双轮驱动 深化“三医”战略布局
Core Insights - The company held a performance briefing for the first half of 2025, discussing operational results and future plans, focusing on AI commercialization, digital healthcare, and cost reduction strategies [1] - The company achieved a revenue of 95.53 million yuan in the reporting period, optimizing its business structure and maintaining a leading position in the digital healthcare sector [2] Group 1: Business Performance - In the first half of 2025, the company actively responded to market changes and optimized its business structure, focusing on the integration of healthcare, medical insurance, and pharmaceuticals [1] - The company’s revenue reached 95.53 million yuan, with significant achievements in digital medical insurance, including winning a bid for a drug procurement subsystem project worth 10.66 million yuan [2] - The company holds a market share of 40.5% in payment methods and 17.4% in fund supervision, leading the industry in bid-winning scale [2] Group 2: Strategic Focus - The company is concentrating on four core business areas: comprehensive management of medical insurance funds, medical quality and safety services, drug and device regulation, and innovative health services [1] - In the second half of 2025, the company aims for steady revenue growth and cost reduction, focusing on AI model empowerment, deepening data application, and advancing comprehensive reforms [2] - The company is accelerating its AI transformation in the digital healthcare sector, launching core products like Intelligent Review 2.0 and promoting a smart service ecosystem in disease prevention and control [2]
AI与数据双轮驱动,深化“三医”战略布局 国新健康2025年半年度业绩说明会成功举办
2025年上半年,国新健康积极应对市场变化,持续优化业务结构,巩固"三医"基本盘,加速培育医疗健 康大数据创新业务,推动AI与医保、医疗、医药及健康服务的深度融合。聚焦医保基金综合管理服 务、医疗质量安全服务、药械监管与药企服务、健康服务创新,业务已覆盖全国29个省(自治区、直辖 市)的200多个地区。 报告期内,国新健康实现营业收入9553万元,业务结构进一步优化。数字医保领域,国新健康持续巩固 领先地位,与国家医保局合作实现多项突破。成功中标药品招采子系统及金额1066万元的医保飞行检查 等服务项目,承担国家追溯码应用研究课题,上半年在支付方式与基金监管市场占有率分别达40.5%和 17.4%,中标规模居行业首位。数字医药板块发展势头强劲,成功签约重庆"渝药安"、浙江药监局一体 化平台等项目,MDI项目实现新突破,DRO业务储备丰富。数字医疗板块不断加快AI转型,推出智能 审核2.0等产品,并积极布局疾控领域,推动"医院—疾控—卫健委"智慧服务生态建设。健康服务业务 稳步推进,优化慢病管理,多个慢病管理中心投入运营。 9月16日下午,国新健康保障服务集团股份有限公司(以下简称"国新健康",股票代码:000 ...